DTPa-HBV-IPV/Hib

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaHaemophilus Influenzae Type bHepatitis BPoliomyelitisTetanus

Phase 2

Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine

CompletedNCT00289796

GlaxoSmithKlineHepatitis B

Start: 2004-07-31End: 2006-12-31Updated: 2017-02-08

Phase 3

Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine

CompletedNCT00325143

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +2

Start: 2003-12-01End: 2007-02-01Updated: 2018-06-06

Phase 4

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

CompletedNCT04535037

GlaxoSmithKlineDiphtheria

Start: 2021-05-26End: 2022-07-25Updated: 2024-08-27

Related Papers

Disparate kinetics in immune response of two different <i>Haemophilus influenzae</i> type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule

Human Vaccines & Immunotherapeutics2024-04-302 citations